Each year, the global oncology community flocks to Chicago to convene at the American Society of Clinical Oncology’s ann | Each year, the global oncology community descends on Chicago for ASCO, where buzzy data drops, practice-changing posters and packed sessions offer a look at where cancer care is headed next. In this week’s episode of “The Top Line,” Fierce Biotech’s Darren Incorvaia and Fierce Pharma’s Zoey Becker and Angus Liu break down the biggest takeaways from their weekend reporting live from the Windy City, from “nutty” in vivo CAR-T data to a historic first for a Chinese biotech asset.

Readouts in rare blood cancers like myelofibrosis, WM and CLL are attracting keen interest at this year’s ASCO conference.

In 2017, a little-known company called Nanjing Legend Biotech walked into the ASCO annual meeting at the 11th hour, dropped a 100% objective response rate for a cell therapy that…